Medicare poised to negotiate drug prices; data on schizophrenia drug points to new treatment approach

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

STAT+: For the second time, Pfizer tries a warranty in response to concerns over high drug costs By Ed Silverman Mark Lennihan/AP “I think there’s good appetite for these kinds of arrangements and I expect to see more," said Jayson Slotnick of Health Policy Strategies. Read More STAT+: Karuna Therapeutics' schizophrenia drug achieves study goals, heralding new treatment approach By Adam Feuerstein APStock If approved, the Karuna drug would usher in the first new class of medicines for the treatment of schizophrenia in decades. Read More In a massive victory for Democrats, Medicare is poised to negotiate drug prices By Rachel Cohrs Manuel Balce Ceneta/AP President Biden is on the verge of his own crowning health care achievement to call, in his words, a BFD: Medicare negotiating drug prices. Read More Sponsor content by STAT Events Biomarkers: The Foundation of Personalized Oncology Register for a virtual event on August 17 to hear researchers, academics, and business leaders discuss what recent innovations in biomarkers mean for the future of cancer treatments. STAT+: The Senate's drug pricing bill is an inevitable solution. It will still have plenty of unintended consequences By Matthew Herper Molly Ferguson for STAT There’s almost no doubt drug pricing legislation like this will have some impact on pharma innovation. But the status quo was untenable. Read More STAT+: At pioneering center for gene therapy, Jim Wilson presided over toxic, abusive workplace, staffers say By Allison DeAngelis and Adam Feuerstein and Jason Mast Mike Reddy for STAT A STAT investigation reveals a darker side to Jim Wilson's leadership of the Gene Therapy Program, the university research program he runs. Read More Monday, August 8, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser